[ back to News ]

Concert Pharmaceuticals to Participate in the Private Company Forum at the 30th Annual Goldman Sachs Global Healthcare Conference

June 1 , 2009

LEXINGTON, Mass -- Concert Pharmaceuticals, Inc. announced today its participation in the private company forum at the 30th Annual Goldman Sachs Global Healthcare Conference on Monday, June 8, 2009 from 3:30 – 5:30 p.m. Eastern Time.  Roger Tung, Ph.D., President and Chief Executive Officer, and Nancy Stuart, Chief Operating Officer, will be available to discuss the Company during the forum.  The conference will be held June 8 – 11, 2009 at the Grand Hyatt Hotel in New York City.  

About Concert

Concert Pharmaceuticals is a clinical stage biotechnology company focused on the application of deuterium chemistry to create novel small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development.  The Company has a broad research pipeline encompassing many therapeutic areas including renal disease, infectious disease, and cardiovascular disease, among others.  Its lead development candidate is the HIV protease inhibitor CTP-518.  Founded in 2006, Concert has raised more than $96 million from leading venture capitalists and institutional investors.  For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.

CoNCERT and CoNCERT Pharmaceuticals are trademarks of Concert Pharmaceuticals, Inc.

[ back to top ]